OS Therapies Announces Nationwide Open Enrollment of Remaining 36 to 42 Patients in Phase IIb Trial of OST-HER2 (Listeria monocytogenes) in Recurred, Resected Osteosarcoma

/PRNewswire/ -- OS Therapies, a research and clinical-stage biopharmaceutical company announced today that the Data Safety & Monitoring Committee (DSMC)...

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Philadelphia ,Pennsylvania ,United States ,Connecticut ,Miriam Cohen ,Johns Hopkins Baltimore ,Data Safety Monitoring Committee ,Jude Children Research Hospital ,Kaiser Permanente Downey Medical Center ,Osteosarcoma Community ,Hackensack University Medical Center ,Os Therapies Inc ,Ut Southwestern Children Medical Center ,Data Safety ,Monitoring Committee ,Resected Osteosarcoma ,Osteosarcoma Collaborative ,Overall Survival ,Rare Disease Designation ,Orphan Designations ,Break Through Designation ,Os Therapies ,